» Articles » PMID: 27313636

The Correlation Between Serum Adipokines and Liver Cell Damage in Non-Alcoholic Fatty Liver Disease

Overview
Journal Hepat Mon
Publisher Brieflands
Specialty Gastroenterology
Date 2016 Jun 18
PMID 27313636
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic hepatitis, which can lead to cirrhosis and hepatocellular carcinoma.

Objectives: The aim of the study was to evaluate the correlation between serum adipocytokines and the histologic findings of the liver in patients with non-alcoholic fatty liver disease (NAFLD).

Patients And Methods: This case-control study was performed on those with persistent elevated liver enzymes and with evidence of fatty liver in ultrasonography. After exclusion of patients with other etiologies causing abnormal liver function tests, the resulting patients underwent liver biopsies. NAFLD was diagnosed based on liver histology according to the Brunt scoring system.

Results: Waist circumferences and levels of blood glucose (after fasting), insulin, triglycerides, alanine aminotransferases (ALT), and aspartate aminotransferases (AST) were higher in patients with NAFLD than in those in the control group. ALT, AST, and gamma glutamine transferase (GGT) levels were lower in patients with liver steatosis of a grade of less than 33% than those with higher degrees of steatosis. Serum low-density lipoprotein (LDL), cholesterol, and hepcidin levels were significantly higher in those with lobular inflammation of grade 0 - 1 than in those with inflammation of grade 2 - 3 (Brunt score). Meanwhile, AST was significantly lower in those with lobular inflammation of grade 1 than in those with grade 2-3. Hepcidin and resistin levels were significantly higher in patients with moderate to severe fibrosis than in those with mild fibrosis.

Conclusions: It seems that surrogate liver function tests and adipocytokine levels were correlated with the histologic findings of the liver.

Citing Articles

The serum hepcidin and the hepcidin/ferritin ratio in NAFLD: a systematic review and meta-analysis.

Song J, Wang H, Gao X, Yang F, Zhu X, Qiao G BMC Gastroenterol. 2025; 25(1):62.

PMID: 39915727 PMC: 11804044. DOI: 10.1186/s12876-025-03620-9.


The Effect of a Multidisciplinary Lifestyle Intervention Program on Apelin-12, Vaspin and Resistin Concentrations in Children and Adolescents with Overweight and Obesity.

Karampatsou S, Paltoglou G, Genitsaridi S, Kassari P, Charmandari E Nutrients. 2024; 16(21).

PMID: 39519480 PMC: 11547676. DOI: 10.3390/nu16213646.


Relationship of serum adiponectin and resistin levels with the severity of liver fibrosis in patients with chronic hepatitis B.

Custovic N, Rasic S J Med Biochem. 2022; 41(2):176-183.

PMID: 35510200 PMC: 9010048. DOI: 10.5937/jomb0-33793.


Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease.

Ghezelbash B, Shahrokhi N, Khaksari M, Asadikaram G, Shahrokhi M, Shirazpour S Chin J Integr Med. 2022; 28(6):531-537.

PMID: 35258780 DOI: 10.1007/s11655-022-3307-3.


Serum Resistin Levels in Adult Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.

Han D, Chen J, Liu S, Zhang Z, Zhao Z, Jin W J Clin Transl Hepatol. 2021; 9(4):484-493.

PMID: 34447677 PMC: 8369026. DOI: 10.14218/JCTH.2021.00018.


References
1.
Schaffler A, Scholmerich J, Buchler C . Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005; 2(6):273-80. DOI: 10.1038/ncpgasthep0186. View

2.
Brunt E, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B . Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94(9):2467-74. DOI: 10.1111/j.1572-0241.1999.01377.x. View

3.
Duan X, Qiao L, Fan J . Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2012; 11(1):18-27. DOI: 10.1016/s1499-3872(11)60120-3. View

4.
Aller R, de Luis D, Izaola O, Gonzalez Sagrado M, Conde R, Velasco M . Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci. 2008; 54(8):1772-7. DOI: 10.1007/s10620-008-0539-9. View

5.
Gatselis N, Ntaios G, Makaritsis K, Dalekos G . Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med. 2013; 14(2):121-31. DOI: 10.1007/s10238-012-0227-0. View